Please read full Prescribing
Information
, including Boxed WARNING.

 
 
 

helpful resources.

 

The tools and documentation here can be important resources in securing treatment for your patients and getting them started on that treatment right away.

 
 

formulary lookup.

Check NUPLAZID approvals by your patient’s insurance provider to get a better sense of the cost and coverage options available to them.

 
GET STARTED
 

prior authorization.

Complete prior authorization that may be necessary to secure NUPLAZID coverage with your patient’s insurance provider.

 
GET STARTED
 
 

This information is intended as a guide. Coverage and costs may differ between private and government insurance plans, and are subject to change. Please check with the health plan to confirm coverage for individual patients.

 
 
 
 

useful downloads. ?

LETTER OF APPEAL: Your patient may need a letter of appeal if a previous authorization request has been denied.

LETTER OF MEDICAL NECESSITY: You may need to document a patient’s medical necessity for treatment to get insurance coverage.

 

The following downloadable tools can help you more easily prescribe NUPLAZID and introduce patients and caregivers to the benefits of Acadia Connect.

 
TREATMENT FORM  ( PDF)
 
LTC SERVICE REQUEST FORM  ( PDF)
 
LETTER OF MEDICAL NECESSITY  ( DOCX)
 
LETTER OF APPEAL  ( DOCX)
 
PATIENT BROCHURE  ( PDF)
 
 
 

Your patient’s NUPLAZID prescription may only
be filled at one of the following pharmacies*:

 

*If another pharmacy is selected, the prescription may not be filled.

Please read full Prescribing Information, including Boxed WARNING.

 
 
 
 

enroll your patients.

To start these services for you and your patients, complete our simple online prescription and enrollment form.

START ENROLLMENT
 
 
Connect with us:
1-844-737-2223
Monday–Friday,
8:00 am to
8:00 pm ET
 
 
 
Important Safety Information and Indication for NUPLAZID® (pimavanserin)
 
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
 
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
 
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation
    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.
    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
  • Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
  • Drug Interactions:
    • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
 

Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.